StockData
Royalty Pharma plc logo

Royalty Pharma plc (RPRX) stock

RPRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 8/3051% above fair value
$68.67−0.01 (-0.01%)

Close on Nov 18, 2026Market cap $39.49BP/E 39.0Yield –

Royalty Pharma net income

Net income is the profit left for shareholders after every expense, interest and tax.

Royalty Pharma's net income for the twelve months ending Jun 30, 2026 was $815.00M, down 20.4% year over year. For fiscal 2025 it was $770.95M, down 10.2% from the year before. The highest annual figure on record is $2.35B in fiscal 2019.

Annual net income

PeriodPeriod endValueChange
FY2025Dec 31, 2025$770.95M-10.2%
FY2024Dec 31, 2024$858.98M-24.3%
FY2023Dec 31, 2023$1.13B+2549.5%
FY2022Dec 31, 2022$42.83M-93.1%
FY2021Dec 31, 2021$619.73M-36.4%
FY2020Dec 31, 2020$975.04M-58.5%
FY2019Dec 31, 2019$2.35B+70.5%
FY2018Dec 31, 2018$1.38B–

Quarterly net income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$17.88M-44.4%
Q1 FY2026Mar 31, 2026$294.69M+23.1%
Q4 FY2025Dec 31, 2025$214.21M+2.9%
Q3 FY2025Sep 30, 2025$288.22M-47.0%
Q2 FY2025Jun 30, 2025$32.18M-68.5%
Q1 FY2025Mar 31, 2025$239.35M+4909.4%
Q4 FY2024Dec 31, 2024$208.21M-57.9%
Q3 FY2024Sep 30, 2024$543.99M+654.3%
Q2 FY2024Jun 30, 2024$102.00M-55.2%
Q1 FY2024Mar 31, 2024$4.78M-98.6%
Q4 FY2023Dec 31, 2023$494.34M–
Q3 FY2023Sep 30, 2023$72.11M-49.4%
Q2 FY2023Jun 30, 2023$227.63M-25.2%
Q1 FY2023Mar 31, 2023$340.76M+558.3%
Q4 FY2022Dec 31, 2022-$456.08M-5870.3%
Q3 FY2022Sep 30, 2022$142.65M+40.0%
Q2 FY2022Jun 30, 2022$304.50M-30.9%
Q1 FY2022Mar 31, 2022$51.76M-25.1%
Q4 FY2021Dec 31, 2021$7.90M-95.4%
Q3 FY2021Sep 30, 2021$101.93M-64.9%
Q2 FY2021Jun 30, 2021$440.78M-0.3%
Q1 FY2021Mar 31, 2021$69.12M-3.0%
Q4 FY2020Dec 31, 2020$171.09M-88.0%
Q3 FY2020Sep 30, 2020$290.63M-28.9%
Q2 FY2020Jun 30, 2020$442.07M+191.4%
Q1 FY2020Mar 31, 2020$71.24M–
Q4 FY2019Dec 31, 2019$1.42B–
Q3 FY2019Sep 30, 2019$408.98M–
Q2 FY2019Jun 30, 2019$151.71M–

More Royalty Pharma figures

See a number that looks wrong?